From Information to Intelligence: Why Healthcare's Future Competitive Advantage Isn't More Data
Over the past few years, data science and digital transformation have captured the attention of life sciences and healthcare leaders.
DeepMind has been among the pioneers. Its collaboration with Moorfields demonstrated how Artificial Intelligence could support clinical interpretation in ophthalmology¹. Its AlphaFold breakthrough that won Demis Hassabis a Nobel Prize transformed protein structure prediction, accelerating biological research on a scale few would have imagined only a decade ago². Most recently, Isomorphic Labs has begun translating these advances into pharmaceutical research through strategic partnerships aimed at reshaping drug discovery³.
Image: Unsplash
These are often presented as separate stories. One belongs to clinical AI. Another to computational biology. The third to pharmaceutical R&D. But I believe they are all evidence of the same AI-powered transition, in the nature and economics of knowledge itself.
Over healthcare’s history, knowledge has been difficult to generate, expensive to acquire and validate – eg via randomized controlled trials – and painfully slow to disseminate. In my experience, the oft-quoted 17 years from insight to routine application is not an exaggeration.
Raw data and information have been the scarce resource around which many of our institutions, incentives and professional models evolved, and are the basis of the success of huge companies like Epic and Oracle/Cerner.
The assumption that the accumulation of such data and information is pivotal is beginning to change.
From Information to Intelligence
In healthcare, as elsewhere, we have often pointed to the chain of value: Data > Information > Knowledge > Wisdom but found ourselves stuck somewhere in stage 3, with human ability to absorb, interpret and recall clinical knowledge often the bottleneck. Wider and wider application of artificial intelligence has the potential to unblock the process, and shifts the key challenge from information accumulation and analysis to how AI-powered knowledge is deployed across the organisation.
As AI reduces the cost of generating and interpreting knowledge, information itself becomes progressively less scarce. Competitive advantage therefore begins to move elsewhere. Increasingly, it will depend on an organisation's ability to transform intelligence into consistently better decisions.
Information helps us understand what is happening; Intelligence helps us understand why it matters; Judgement determines what should happen next.
Artificial Intelligence is rapidly strengthening the first two. The third remains, fundamentally, a human responsibility and therefore a leadership challenge.
The Information - Intelligence - Action Gaps
Every significant decision in healthcare exists within competing priorities: clinical evidence, operational pressures, regulatory constraints, economic constraints, and the patient’s own goals and their participation in decisions and implementation. No algorithm resolves these tensions: judgement does.
The organisations most likely to succeed in the coming decade will not necessarily be those possessing the largest datasets or deploying the greatest number of AI tools. They will be organisations that redesign decision-making itself. Take the complex area of auto-immune disease, which has long baffled both clinicians and biopharma companies. Both have been stuck on disease labels, like lupus or psoriatic arthritis. AI-assisted analysis reveals a diversity of underlying immune dysfunctions, but this knowledge needs to be presented to drug developers and treating clinicians in an actionable format, and then built into their decision processes.
Leadership Beyond Technology
Leaders in this new era will develop governance that enables human expertise and machine intelligence to reinforce one another. Technology does not replace organisational judgement. It amplifies the quality of the judgement that already exists.
This is why I increasingly see AI as changing the nature of leadership as much as the nature of healthcare. For years, leaders have quite rightly focused on digitisation, automation and adoption. Those priorities remain important, but they are no longer sufficient.
The organisations that will create sustained advantage are unlikely to be distinguished simply by their technology stack. They will be distinguished by the quality of the decisions they make after the technology has been deployed. This shifts the conversation towards governance, organisational design, accountability and leadership capability.
In other words, AI is not simply asking organisations to adopt new technologies. It is asking them to rethink how they make decisions.
History tends to remember breakthrough technologies. Less attention is given to the new organisational models that allow those technologies to create lasting value. Leaders, whether in healthcare or biopharma, need to ask: which of our strategies, organisational structures and personnel development models are still designed for the world we are leaving rather than the dramatically new one we are entering?
